159938 医药
已收盘 05-08 15:00:00
资讯
新帖
简况
沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”
21世纪经济报道 · 05-08 21:44
沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”
A股开盘速递 | 三大股指集体低开 AI应用、医药、白酒板块涨幅居前
智通财经网 · 05-08 09:34
A股开盘速递 | 三大股指集体低开 AI应用、医药、白酒板块涨幅居前
华昊中天医药-B(02563)建议采纳购股权计划
智通财经 · 05-07 23:05
华昊中天医药-B(02563)建议采纳购股权计划
创胜集团医药-B(06628.HK)获执行董事、主席兼首席执行官钱雪明增持3万股
中金财经 · 05-07 22:27
创胜集团医药-B(06628.HK)获执行董事、主席兼首席执行官钱雪明增持3万股
热景生物(688068.SH)控股子公司舜景医药获得北京市“专精特新”中小企业证书
智通财经 · 05-07 21:17
热景生物(688068.SH)控股子公司舜景医药获得北京市“专精特新”中小企业证书
5月7日星昊医药现1笔折价30.82%的大宗交易 合计成交162.42万元
证券之星 · 05-07 17:17
5月7日星昊医药现1笔折价30.82%的大宗交易 合计成交162.42万元
5月7日悦康药业涨5.21%，富国医药创新股票A基金重仓该股
证券之星 · 05-07 16:33
5月7日悦康药业涨5.21%，富国医药创新股票A基金重仓该股
联化科技：专注于植保、医药和功能化学品等业务
证券之星 · 05-07 16:30
联化科技：专注于植保、医药和功能化学品等业务
【新股IPO】丹诺医药通过港交所上市聆讯
金吾财讯 · 05-07 08:58
【新股IPO】丹诺医药通过港交所上市聆讯
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
每日经济新闻 · 05-07 07:00
时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参
森萱医药：4月30日副总经理姜春娟减持股份合计1.88万股
证券之星 · 05-06 19:01
森萱医药：4月30日副总经理姜春娟减持股份合计1.88万股
新股消息 | 礼邦医药冲刺港股：美信罗撑起商业化底盘，AP306出海打开全球想象
智通财经网 · 05-06
新股消息 | 礼邦医药冲刺港股：美信罗撑起商业化底盘，AP306出海打开全球想象
多举措做强藏医药事业
青海日报 · 05-06
多举措做强藏医药事业
中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权
证券之星 · 05-01
中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权
万润股份：公司收入按产品分类主要包括功能性材料、生命科学与医药两类
证券之星 · 04-30
万润股份：公司收入按产品分类主要包括功能性材料、生命科学与医药两类
4月30日山外山涨5.27%，圆信永丰医药健康A基金重仓该股
证券之星 · 04-30
4月30日山外山涨5.27%，圆信永丰医药健康A基金重仓该股
4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股
证券之星 · 04-30
4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股
《Brand Finance 2026全球医药品牌价值榜》出炉 中国药企品牌价值达120.9亿美元
新浪财经 · 04-30
《Brand Finance 2026全球医药品牌价值榜》出炉 中国药企品牌价值达120.9亿美元
新股前瞻|在研管线远水难救近渴，汇伦医药何时走出“阵痛期”？
智通财经 · 04-30
新股前瞻|在研管线远水难救近渴，汇伦医药何时走出“阵痛期”？
创新医疗（002173）披露为鸿润医药提供800万元授信担保公告，4月29日股价上涨1.09%
证券之星 · 04-29
创新医疗（002173）披露为鸿润医药提供800万元授信担保公告，4月29日股价上涨1.09%
加载更多
公司概况
公司名称：
--
所属市场：
上市日期：
--
主营业务：
发行价格：
--
{"stockData":{"symbol":"159938","market":"SZ","secType":"STK","nameCN":"医药","latestPrice":0.639,"timestamp":1778223780000,"preClose":0.643,"halted":0,"volume":36398400,"delay":0,"changeRate":-0.0062,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.004,"latestTime":"05-08 15:00:00","open":0.643,"high":0.645,"low":0.637,"amount":23256700,"amplitude":0.0124,"askPrice":0.639,"askSize":4763,"bidPrice":0.638,"bidSize":417,"shortable":0,"etf":1,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":0.643,"symbolType":"fund","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":0.707,"lowLimit":0.579,"ibTradeSell":false,"ibTradeBuySell":true,"isCdr":false,"pbRate":0,"committee":0.247346,"marketValue":0,"turnoverRate":0,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-11。","floatMarketCap":0},"requestUrl":"/m/hq/s/159938","defaultTab":"news","newsList":[{"id":"2633452589","title":"沪市主板医药股首季业绩稳中略升，龙头企业提供“强支撑”","url":"https://stock-news.laohu8.com/highlight/detail?id=2633452589","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633452589?lang=zh_cn&edition=full","pubTime":"2026-05-08 21:44","pubTimestamp":1778247892,"startTime":"0","endTime":"0","summary":"一季报落幕，沪市一批医药龙头企业首季展现出的业绩也提振人心。数据显示，沪市主板111家医药类公司2026年一季度合计实现营业收入3305.5亿元，同比小幅上升2%，合计实现净利润247亿元，同比上升0.5%。其中，药明康德、恒瑞医药分别贡献了超过46.5亿元和22.8亿元的净利润，两公司均实现了一季度营收、净利润的显著增长，为整个行业首季表现提供了强力支撑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083731825533.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083731825533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","159938","09939","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633102550","title":"A股开盘速递 | 三大股指集体低开 AI应用、医药、白酒板块涨幅居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2633102550","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633102550?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:34","pubTimestamp":1778204068,"startTime":"0","endTime":"0","summary":"5月8日，A股三大股指集体低开，沪指跌0.39%，创业板指跌1.07%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260508/20260508093454_87999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260508/20260508093454_87999.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1515","09939","159938","AIQ","BK4585","BK1161","BK4588","159982","BK1574","399300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633129544","title":"华昊中天医药-B(02563)建议采纳购股权计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2633129544","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633129544?lang=zh_cn&edition=full","pubTime":"2026-05-07 23:05","pubTimestamp":1778166320,"startTime":"0","endTime":"0","summary":"智通财经APP讯，华昊中天医药-B(02563)公布，于2026年5月6日，董事会议决根据上市规则第17章采纳购股权计划，以就参与者为集团的增长及发展作出的贡献或潜在贡献向彼等提供激励或奖励。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK1574","09939","02563","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633085125","title":"创胜集团医药-B(06628.HK)获执行董事、主席兼首席执行官钱雪明增持3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633085125","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633085125?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:27","pubTimestamp":1778164023,"startTime":"0","endTime":"0","summary":"格隆汇5月7日丨根据联交所最新权益披露资料显示，2026年5月5日，创胜集团医药-B(06628.HK)获执行董事、主席兼首席执行官钱雪明在场内以每股均价2.1433港元增持3万股，涉资约6.43万港元。\r\n\r\n 增持后，钱雪明最新持股数目为3806万股，持股比例由8.35%上升至8.36%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202605/07/20260507752769.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202605/07/20260507752769.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260507/32207450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06628","BK1161","09939","BK1515","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633814006","title":"热景生物(688068.SH)控股子公司舜景医药获得北京市“专精特新”中小企业证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2633814006","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633814006?lang=zh_cn&edition=full","pubTime":"2026-05-07 21:17","pubTimestamp":1778159821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司控股子公司北京舜景生物医药技术有限公司(简称“舜景医药”)收到了北京市经济和信息化局颁发的证书，舜景医药被认定为北京市“专精特新”中小企业，有效期为2026年4月至2029年4月。舜景医药本次获得北京市“专精特新”中小企业证书，是对舜景医药在生物创新药领域的技术水平、创新能力及综合实力的认可，有利于提高公司及子公司核心竞争力和品牌影响力，有助于形成持续的创新能力和创新机制，对公司经营发展产生积极影响和促进作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439245.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688068","09939","159938","BK1515","BK1161","BK1574","399267","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633111582","title":"5月7日星昊医药现1笔折价30.82%的大宗交易 合计成交162.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633111582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633111582?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:17","pubTimestamp":1778145452,"startTime":"0","endTime":"0","summary":"证券之星消息，5月7日星昊医药发生大宗交易，交易数据如下：大宗交易成交价格12.64元，相对当日收盘价折价30.82%，成交12.85万股，成交金额162.42万元，买方营业部为招商证券股份有限公司宜昌胜利四路证券营业部，卖方营业部为国泰海通证券股份有限公司湖北武汉光谷营业部。近三个月该股共发生1笔大宗交易，合计成交1285.0手，折价成交1笔。截至2026年5月7日收盘，星昊医药报收于18.27元，上涨1.22%，换手率1.3%，成交量1.61万手，成交额2847.6万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700028016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1161","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633370116","title":"5月7日悦康药业涨5.21%，富国医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633370116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633370116?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:33","pubTimestamp":1778142828,"startTime":"0","endTime":"0","summary":"证券之星消息，5月7日悦康药业涨5.21%，收盘报21.21元，换手率2.95%，成交量13.28万手，成交额2.75亿元。重仓悦康药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为富国基金的富国医药创新股票A。富国医药创新股票A目前规模为11.12亿元，最新净值1.6834，较上一交易日上涨0.45%，近一年上涨24.36%。该公募基金现任基金经理为赵伟 王超。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700026719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","159938","BK1515","BK1161","BK1574","BK0239","688658"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633116354","title":"联化科技：专注于植保、医药和功能化学品等业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633116354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633116354?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:30","pubTimestamp":1778142638,"startTime":"0","endTime":"0","summary":"证券之星消息，联化科技05月07日在投资者关系平台上答复投资者关心的问题。通过事业部团队管理的运作模式，专注于做好植保、医药和功能化学品和设备与工程服务业务，更好地服务我们的客户从而赢得竞争的胜利。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700026617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0118","BK0229","BK0028","09939","159938","BK1161","002250","BK1574","BK0188","BK0070","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633275164","title":"【新股IPO】丹诺医药通过港交所上市聆讯","url":"https://stock-news.laohu8.com/highlight/detail?id=2633275164","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633275164?lang=zh_cn&edition=full","pubTime":"2026-05-07 08:58","pubTimestamp":1778115495,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所5月6日披露，丹诺医药通过港交所上市聆讯，中信证券、农银国际为联席保荐人。截至最后实际可行日期，公司已建立一条由七项创新项目组成的管线，包括两项核心产品，即：利福特尼唑及利福喹酮。公司拟将募资所得用于核心产品的研究、开发、注册备案及商业化；为TNP-2092口服制剂的研发提供资金；研发公司的其他候选产品；建设自有工厂；及作营运资金及其他一般公司用途。","market":"nz","thumbnail":"https://static.szfiu.com/news/20220324/NjMyZjUxNTAyODM5OTc0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20220324/NjMyZjUxNTAyODM5OTc0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980752","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","159938","09939","HEXmain","BK1574","IPOS","BK1161","SPCX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633512166","title":"时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作；莎普爱思终止购买上海勤礼实业100%股权｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2633512166","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633512166?lang=zh_cn&edition=full","pubTime":"2026-05-07 07:00","pubTimestamp":1778108408,"startTime":"0","endTime":"0","summary":"丨2026年5月7日星期四丨NO.1时安生物与GSK就寡核苷酸新药达成超10亿美元授权合作时安生物宣布，与葛兰素史克（GSK）就SA030达成一项中国市场以外的全球独家许可协议。葛兰素史克将支付首付款，以及未来基于成功达成的开发、注册与商业化里程碑付款，总额最高达10.05亿美元；同时将按中国以外的全球产品净销售额支付分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073729101163.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073729101163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["603168","BK0239","LU1829250122.USD","BK1161","GSK","BK4588","BK4532","BK4585","BK4007","GSK.UK","09939","BK1574","GSKH","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633182307","title":"森萱医药：4月30日副总经理姜春娟减持股份合计1.88万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633182307","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633182307?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:01","pubTimestamp":1778065290,"startTime":"0","endTime":"0","summary":"证券之星消息，根据5月6日市场公开信息、上市公司公告及交易所披露数据整理，森萱医药最新董监高及相关人员股份变动情况：2026年4月30日公司副总经理,董事姜春娟共减持公司股份1.88万股，占公司总股本为0.0044%。变动期间公司股价上涨3.74%，4月30日当日收盘报10.25元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","159938","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633974222","title":"新股消息 | 礼邦医药冲刺港股：美信罗撑起商业化底盘，AP306出海打开全球想象","url":"https://stock-news.laohu8.com/highlight/detail?id=2633974222","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633974222?lang=zh_cn&edition=full","pubTime":"2026-05-06 10:21","pubTimestamp":1778034074,"startTime":"0","endTime":"0","summary":"礼邦医药此次递表的一大亮点，是其已通过美信罗建立起商业化收入基础。2024年，全球高磷血症药物市场规模达15亿美元，预计2035年将增至60亿美元。公司称，AP306是全球首款且截至最后实际可行日期临床开发中唯一一款用于治疗高磷血症的泛磷转运蛋白抑制剂。2025年12月，礼邦医药与R1 Therapeutics就AP306订立合作及许可协议。按照招股书披露，公司及R1预计于2026年第二季度启动AP306的IIb期多中心临床试验，并于2027年第二季度完成该试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","BK4588","BK4585","VXUS","BK1574","09939","BK1515","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633686940","title":"多举措做强藏医药事业","url":"https://stock-news.laohu8.com/highlight/detail?id=2633686940","media":"青海日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633686940?lang=zh_cn&edition=full","pubTime":"2026-05-06 01:41","pubTimestamp":1778002860,"startTime":"0","endTime":"0","summary":"泽库县立足高原独特药材资源，将中藏医药纳入全域发展规划，出台专项扶持政策，近三年投入1330.33万元专项资金，针对性提升高原中藏医药服务能力，让藏医药适配牧区群众健康需求。聚焦高原人才培育，通过名师带徒、野外辨药、外出进修等贴合高原实际的方式，培养本土中藏医药人才171人，建成全国名老中藏医传承工作室，定向免费培养适配高原的中藏医本科医学生9人。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-05-06/doc-inhwwrqz6278366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09939","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632650371","title":"中国医药新注册《医药医疗健康业务数据分析软件V1.0》等4个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2632650371","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632650371?lang=zh_cn&edition=full","pubTime":"2026-05-01 01:56","pubTimestamp":1777571773,"startTime":"0","endTime":"0","summary":"证券之星消息，近日中国医药新注册了4个项目的软件著作权，包括《医药医疗健康业务数据分析软件V1.0》、《审计追责报告汇总软件V1.0》、《销售预测分析系统V1.0》、《投资报告管理系统V1.0》等。今年以来中国医药新注册软件著作权10个。通过天眼查大数据分析，中国医药健康产业股份有限公司共对外投资了29家企业，参与招投标项目817次；财产线索方面有商标信息5条，专利信息4条，著作权信息6条；此外企业还拥有行政许可16个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100000610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK1161","159180","BK0185","159760","09939","BK0082","BK1574","BK1515","BK0028","BK0188","BK0175","BK0250","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631897586","title":"万润股份：公司收入按产品分类主要包括功能性材料、生命科学与医药两类","url":"https://stock-news.laohu8.com/highlight/detail?id=2631897586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631897586?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:06","pubTimestamp":1777539975,"startTime":"0","endTime":"0","summary":"证券之星消息，万润股份04月30日在投资者关系平台上答复投资者关心的问题。公司收入按产品分类主要包括功能性材料、生命科学与医药两类。因在电子信息材料产业、环保材料产业、新能源材料产业领域的产品均属于功能性材料，所以按产品分类划归功能性材料。另外也是为了避免各具体类别产品营业收入、营业成本、毛利率等详细信息被同业企业了解后可能产生的竞争类风险，所以按目前口径披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0132","BK0082","BK1161","BK0152","BK1515","BK0229","09939","002643","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631852146","title":"4月30日山外山涨5.27%，圆信永丰医药健康A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631852146","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631852146?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:27","pubTimestamp":1777537668,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日山外山涨5.27%，收盘报17.17元，换手率5.96%，成交量19.05万手，成交额3.29亿元。重仓山外山的公募基金请见下表：该股最近90天内共有1家机构给出评级，增持评级1家。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为圆信永丰基金的圆信永丰医药健康A。圆信永丰医药健康A目前规模为2.66亿元，最新净值1.9551，较上一交易日下跌0.03%，近一年上涨23.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159938","09939","688410","BK1515","150219","BK1161","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631685732","title":"4月30日海创药业涨7.95%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2631685732","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631685732?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:26","pubTimestamp":1777537618,"startTime":"0","endTime":"0","summary":"证券之星消息，4月30日海创药业涨7.95%，收盘报44.0元，换手率2.37%，成交量2.35万手，成交额9947.52万元。该股为创新药、医药概念热股。重仓海创药业的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为16.53亿元，最新净值1.6892，较上一交易日上涨0.33%，近一年上涨24.55%。该公募基金现任基金经理为金笑非。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000053477.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09939","BK1574","BK1515","159938","BK0239","688302"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631683639","title":"《Brand Finance 2026全球医药品牌价值榜》出炉 中国药企品牌价值达120.9亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631683639","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631683639?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:55","pubTimestamp":1777535700,"startTime":"0","endTime":"0","summary":"当地时间2026年4月30日，《Brand Finance2026全球医药品牌价值榜》发布。报告显示，共有10家中国医药企业成功跻身全球医药50强榜单，总品牌价值达120.9亿美元。 该报告包含全球医药品牌价值50强、全球医疗设备品牌价值25强与全球医疗保健服务品牌价值10强的权威排名。 在上榜的中国药企中，国药集团作为中国医药品牌的领军企业，品牌价值增长10.1%至41.4亿美元，稳居全球第11位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-04-30/doc-inhwhkum4189781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159938","09939","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631722055","title":"新股前瞻|在研管线远水难救近渴，汇伦医药何时走出“阵痛期”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2631722055","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631722055?lang=zh_cn&edition=full","pubTime":"2026-04-30 09:58","pubTimestamp":1777514330,"startTime":"0","endTime":"0","summary":"近日，上海汇伦医药股份有限公司向港交所主板提交上市申请书，中信证券为独家保荐人。2024年，汇伦医药跻身中国化药研发实力100强，截至最后实际可行日期，拥有107项已授权专利及109项专利申请。从业绩走势来看，2023年公司营收高增，主要得益于核心产品希为纳在疫情期间的需求爆发。2023年，受COVID-19疫情期间肺部感染病例激增影响，希为纳临床需求爆发，当年贡献收入7.45亿元，占公司总营收的75.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","09939","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631543800","title":"创新医疗（002173）披露为鸿润医药提供800万元授信担保公告，4月29日股价上涨1.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631543800","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631543800?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:19","pubTimestamp":1777472360,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，创新医疗报收于23.19元，较前一交易日上涨1.09%，最新总市值为102.33亿元。该股当日开盘22.62元，最高23.29元，最低22.6元，成交额达3.35亿元，换手率为3.44%。近日，创新医疗管理股份有限公司披露《第七届董事会2026年第二次临时会议决议公告》。公司决定为浙江鸿润医药有限公司在800万元授信额度内向招商银行绍兴诸暨支行申请贷款提供担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900068941.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002173","BK0077","BK0114","BK0096","BK1574","09939","BK1161","BK0236","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778315492085,"stockEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":-0.0259},{"period":"3month","weight":-0.0347},{"period":"6month","weight":-0.0726},{"period":"1year","weight":0.0458},{"period":"ytd","weight":-0.0154}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0463},{"period":"3month","weight":0.0281},{"period":"6month","weight":0.0456},{"period":"1year","weight":0.247},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医药,159938,医药股票,医药股票老虎,医药股票老虎国际,医药行情,医药股票行情,医药股价,医药股市,医药股票价格,医药股票交易,医药股票购买,医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医药(159938)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医药(159938)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}